# Significant decrease in neutralization across 15 of 16 sera tested 7-17 days post symptoms onset.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
E484K

# Significant decrease in neutralization across 15 of 16 sera tested 7-17 days post symptoms onset.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
E484D

# Significant decrease in neutralization across 15 of 16 sera tested 7-17 days post symptoms onset.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
E484A

# Significant decrease in neutralization across 11 of 16 sera tested 7-17 days post symptoms onset.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
S477N

# Significant decrease in neutralization across 4 of 16 sera tested 7-17 days post symptoms onset.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
N450Y

# No effective neutralization in 1 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
T354S

# No effective neutralization in 2 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
L441R

# No effective neutralization in 3 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
K444E

# No effective neutralization in 1 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
G446D

# No effective neutralization in 3 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
G446V

# No effective neutralization in 2 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
N450D

# No effective neutralization in 2 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
N450Y

# No effective neutralization in 3 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
L452R

# No effective neutralization in 2 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
S477G

# No effective neutralization in 2 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
T478I

# No effective neutralization in all 4 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
E484A

# No effective neutralization in all 4 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
E484D

# No effective neutralization in all 4 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
E484G

# No effective neutralization in all 4 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
E484K

# No effective neutralization in 1 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
F486S

# No effective neutralization in 3 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
F490S

# No effective neutralization in 2 out of the 4 sera tested.
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
S477N;S514

# IC50 relative to wildtype drops ~8x in neutralization efficiency between 7-17 days post symptoms onset. 
# Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014 [Journal publication]
F486S

# In 12 convalescent sera more than 2 weeks and less than 2 months post infection, this NTD mutation causes a ~3.5x drop in neutralization efficiency.
# Haslwanter et al. (2021) https://doi.org/10.1101/2021.06.10.447999 [Preprint (BioRxiv); Now published at: https://doi.org/10.1128/mbio.02473-21]
Y145D

# In 12 convalescent sera more than 2 weeks and less than 2 months post infection, this NTD mutation causes a ~3.5x drop in neutralization efficiency.
# Haslwanter et al. (2021) https://doi.org/10.1101/2021.06.10.447999 [Preprint (BioRxiv); Now published at: https://doi.org/10.1128/mbio.02473-21]
K150E

# In 12 convalescent sera more than 2 weeks and less than 2 months post infection, this NTD mutation causes a ~3.5x drop in neutralization efficiency.
# Haslwanter et al. (2021) https://doi.org/10.1101/2021.06.10.447999 [Preprint (BioRxiv); Now published at: https://doi.org/10.1128/mbio.02473-21]
W152R

# Mean 12.4x reduction of NT50 value B.1.621 (Mu) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset. [This is a greater reduction than Beta @ 8.2x]
# Uriu et al. (2021) https://doi.org/10.1101/2021.09.06.459005 [Preprint (BioRxiv); Now published at: https://doi.org/10.1056/nejmc2114706]
T95I;Y144delinsTSN;R346K;E484K;N501Y;D614G;P681H;D950N

# Mean 3.4x reduction of NT50 value for C.37 (Lambda) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.
# Uriu et al. (2021) https://doi.org/10.1101/2021.09.06.459005 [Preprint (BioRxiv); Now published at: https://doi.org/10.1056/nejmc2114706]
G75V;T76I;R246_D253delinsN;L452Q;F490S;D614G;T859N

# Mean 2.7x reduction of NT50 value B.1.427 (Epsilon) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.
# Uriu et al. (2021) https://doi.org/10.1101/2021.09.06.459005 [Preprint (BioRxiv); Now published at: https://doi.org/10.1056/nejmc2114706]
S13I;W152C;L452R;D614G

# Mean 4.0x reduction of NT50 value B.1.617.2 (Delta) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.
# Uriu et al. (2021) https://doi.org/10.1101/2021.09.06.459005 [Preprint (BioRxiv); Now published at: https://doi.org/10.1056/nejmc2114706]
T19R;G142D;S:p.E156del;S:p.F157del;S:p.R158G;L452R;T478K;D614G;P681R;D950N

# Mean 4.1x reduction of NT50 value P.1 (Gamma) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.
# Uriu et al. (2021) https://doi.org/10.1101/2021.09.06.459005 [Preprint (BioRxiv); Now published at: https://doi.org/10.1056/nejmc2114706]
L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;D614G;H655Y;T1027I

# Mean 8.2x reduction of NT50 value B.1.351 (Beta) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.
# Uriu et al. (2021) https://doi.org/10.1101/2021.09.06.459005 [Preprint (BioRxiv); Now published at: https://doi.org/10.1056/nejmc2114706]
L18F;D80A;D215G;R246I;K417N;E484K;N501Y;D614G;A701V

# Mean 2.6x reduction of NT50 value B.1.1.7 (Alpha) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.
# Uriu et al. (2021) https://doi.org/10.1101/2021.09.06.459005 [Preprint (BioRxiv); Now published at: https://doi.org/10.1056/nejmc2114706]
H69del;V70del;Y144del;N501Y;A570D;D614G;P681H;T716I;S982A;D1118H

# Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]
# Wilhelm et al. (2021) https://doi.org/10.1101/2021.08.09.21261704 [Preprint (MedRxiv); Now published at: https://doi.org/10.3390/v13091693]
G142D;E154K;L452R;E484Q;D614G;P681R;Q1071H

# Relative to B.1, Delta (B.1.617.2) shows 3.64x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]
# Wilhelm et al. (2021) https://doi.org/10.1101/2021.08.09.21261704 [Preprint (MedRxiv); Now published at: https://doi.org/10.3390/v13091693]
T19R;T95I;G142D;F157del;R158del;A222V;L452R;T478K;D614G;P681R;D950N

# Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]
# Wilhelm et al. (2021) https://doi.org/10.1101/2021.08.09.21261704 [Preprint (MedRxiv); Now published at: https://doi.org/10.3390/v13091693]
D614G;L452R

# Artificially constructed HIV-1 pseudovirus with set of mutations drawn from plasma passage escape experiments
# shows ablated neutralization efficacy (NT50 ~ 0) in two of 21 convalescents plasma collected mean 1.3 months post infection.
# Greater than 4-fold reduction was observed in most of the other plasma. 14 vaccinee plasma showed a slightly lower
# reduction in efficacy, albeit from a higher average starting point titre than convalescents.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
V47M;G142E;K378R;V445E;N450D;E484K;Q493R;T604I;F759S;P792H;I931M;V1061M;P1162S

# Artificially constructed HIV-1 pseudovirus with set of mutations drawn from plasma passage escape experiments
# shows ablated neutralization efficacy (NT50 ~ 0) in two of 21 convalescents plasma collected mean 1.3 months post infection.
# Greater than 4-fold reduction was observed in most of the other plasma. 14 vaccinee plasma showed a slightly lower
# reduction in efficacy, albeit from a higher average starting point titre than convalescents.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
S12P;F104S;Y144C;L244P;W258R;K378R;N440K;V445E;G446R;N450D;E484K;P792H;N801D

# Artificially constructed HIV-1 pseudovirus with set of mutations drawn from plasma passage escape experiments
# and mutations from variants of concern completely ablates neutralization in 19 of 21 convalescents plasma collected mean 1.3 months post infection.
# [actual Y145del from manuscript substituted with more common Y144del description]
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
L18F;V47M;H69del;V70del;D80A;Y144del;D215G;L242del;A243del;L244del;W258R;R346S;K417N;N440K;V445E;L455R;A475V;E484K;N501Y;D614G;A701V;P792H;N801D

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
S12P

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
Q14H

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
C15G

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
P25L

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
V47M

# Mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection, but also
# in cell culture without plasma, therefore likely a replication cycle fitness rather than polyclonal immunity escape variant.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
W64R

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
F140S

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
G142E

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
V143G

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
Y145C

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
K147N

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
K147E

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
E154K

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
A243D

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
L244P

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
S247P

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
S254Y

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
Y248H

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
W258R

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
A260V

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
A260T

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
K378R

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
K444T

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
V445E

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
V445M

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
G446R

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
N450D

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
E484K

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
Q493R

# Mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection, but also
# in cell culture without plasma, therefore likely a replication cycle fitness rather than polyclonal immunity escape variant.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
T604I

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
A623T

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
P681S

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
F792H

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
N801D

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
S813I

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
I931M

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
Q1010R

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
V1061M

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
D1118G

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
V1128A

# Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.
# Schmidt et al. (2021) https://doi.org/10.1101/2021.08.06.455491 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41586-021-04005-0]
P1162S

# Pseudotyped viruses for B.1.617 was 2.3-fold resistant to neutralization by convalescent sera compared to wild type - a finding that
# was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay.
# The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617.
# [details on the convalescent patient sera collection are not abundantly clear in the preprint]
# Tada et al. (2021) https://doi.org/10.1101/2021.05.14.444076 [Preprint (BioRxiv); Now published at: https://doi.org/10.1016/j.isci.2021.103341]
L452R;E484Q;D614G

# Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that
# was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay.
# The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.
# [details on the convalescent patient sera collection are not abundantly clear in the preprint]
# Tada et al. (2021) https://doi.org/10.1101/2021.05.14.444076 [Preprint (BioRxiv); Now published at: https://doi.org/10.1016/j.isci.2021.103341]
E484K;D614G

# Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases)
# with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100.
# Only two of the 15 sera achieved 80% neutralization.
# Stamatatos et al. (2021) https://doi.org/10.1126/science.abg9175 [Journal publication]
D80A;D215G;K417N;E484K;N501Y;A701V;D614G

# Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases)
# with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100. 
# Only one of the 15 sera achieved 80% neutralization.
# [compare to 5 and 1 for pseudotype without the deletion]
# Stamatatos et al. (2021) https://doi.org/10.1126/science.abg9175 [Journal publication]
D80A;D215G;L242del;K417N;E484K;N501Y;D614G

# VSV pseudotyped with Y453F reduced inhibition by most of the 13 potent convalescent serum/plasma samples tested, albeit with variable efficiency 
# (median increase of serum/plasma titer required for 50% neutralization [NT50] = 1.62x, range = 1.02x to 3.43x), indicating that this 
# RBD mutation may compromise SARS-CoV-2 control by preexisting neutralizing antibody responses.
# Hoffman et al. (2021) https://doi.org/10.1016/j.celrep.2021.109017 [Journal publication]
Y453F

# 0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe 
# disease 21 to 63 days post-onset. 
# Kuzmina et al. (2021) https://doi.org/10.1016/j.chom.2021.03.008 [Journal publication]
N501Y

# ~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe 
# disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.
# Kuzmina et al. (2021) https://doi.org/10.1016/j.chom.2021.03.008 [Journal publication]
N501Y;K417N;E484K

# Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58 
# convalescent individuals collected up to 9 months after symptoms, similarly neutralized B.1.1.7 and D614G. 
# Planas et al. (2021) https://doi.org/10.1038/s41591-021-01318-5 [Journal publication]
H69del;V70del;Y144del;N501Y;A570D;D614G;P681H;T716I;S982A;D1118H

# Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58 
# convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples 
# lacked any activity against B.1.351. 
# Planas et al. (2021) https://doi.org/10.1038/s41591-021-01318-5 [Journal publication]
L18F;D80A;D215G;L242del;K417N;E484K;N501Y;D614G;A701V

# Approximately 2-fold reduction in 15 ICU patient convalescent plasma neutralization as quantified by measuring virus-encoded 
# luciferase activity in cell lysates at 16-18 h post transduction.
# [PG: note that the virus tested as B.1.617 overlaps only partially with the Spike mutation lists used by PANGO, CDC, etc. for this lineage
# therefore the results should be interpreted carefully as transferable to B.1.617 generally]
# Hoffman et al. (2021) https://doi.org/10.1101/2021.05.04.442663 [Preprint (BioRxiv); Now published at: https://doi.org/10.1016/j.celrep.2021.109415]
R21T;E154K;Q218H;L452R;E484Q;D614G;P681R;H1101D

# Approximately 6-fold reduction in 15 ICU patient convalescent plasma neutralization as quantified by measuring virus-encoded luciferase 
# activity in cell lysates at 16-18 h post transduction.
# Hoffman et al. (2021) https://doi.org/10.1101/2021.05.04.442663 [Preprint (BioRxiv); Now published at: https://doi.org/10.1016/j.celrep.2021.109415]
D80A;L242del;R246I;K417N;E484K;N501Y;A701V

# The most significant loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from
# convalescent plasma was seen against authentic B.1.351 lineage virus (9.2-fold). Neutralization against 10
# convalescent plasma was poorer (18.7x).
# Tang et al. (2021) https://doi.org/10.1101/2021.03.19.436183 [Preprint (BioRxiv); Now published at: https://doi.org/10.1136/annrheumdis-2022-222115]
L18F;D80A;D215G;L242del;A243del;L244del;N501Y;K417N;E484K;D614G 

# Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from
# convalescent plasma was minimal against B.1.249 (1.7-fold). Neutralization against 10
# convalescent plasma was somewhat poorer (3.1-fold).
# Tang et al. (2021) https://doi.org/10.1101/2021.03.19.436183 [Preprint (BioRxiv); Now published at: https://doi.org/10.1136/annrheumdis-2022-222115]
S13I;W152C;L452R

# As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for 
# six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.
# Tang et al. (2021) https://doi.org/10.1101/2021.03.19.436183 [Preprint (BioRxiv); Now published at: https://doi.org/10.1136/annrheumdis-2022-222115]
E484K

# As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for 
# six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.
# Tang et al. (2021) https://doi.org/10.1101/2021.03.19.436183 [Preprint (BioRxiv); Now published at: https://doi.org/10.1136/annrheumdis-2022-222115]
N501Y

# Subtype of the B.1.526 "New York" lineage, lentivirus pseudotyped with this mutation combination in showed no significant 
# change in IC50 serum dilution concentration for 6 convalescent sera.
# Zhou et al. (2021) https://doi.org/10.1101/2021.03.24.436620 [Preprint (BioRxiv); Now published at: https://doi.org/10.1128/mbio.01386-21]
L5F;T95I;D253G;S477N;D614G;A701V

# Subtype of the B.1.526 "New York" lineage, lentivirus pseudotyped with this mutation combination in showed 3.8x reduction in 
# IC50 serum dilution concentration for 6 convalescent sera.
# Zhou et al. (2021) https://doi.org/10.1101/2021.03.24.436620 [Preprint (BioRxiv); Now published at: https://doi.org/10.1128/mbio.01386-21]
L5F;T95I;D253G;E484K;D614G;A701V

# In 9 plasma collected 15 to 28 days after early 2020 infections, neutralization reduced 4.9-fold for
# B.1.427/B.1.429 compared to wildtype (D614G).
# In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization 
# reduced to undetectable levels in many plasma for B.1.427/B.1.429 pseudotyped virus, as well as WT and other VOCs. 
# McCallum et al. (2021) https://doi.org/10.1101/2021.03.31.437925 [Preprint (BioRxiv)]
S13I;W152C;L452R

# In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization 
# reduced to undetectable levels in many plasma for B.1.351 pseudotyped virus, as well as WT and other VOCs. 
# [paper does not detail the B.1.351 variants used, using the most popular as a stad in]
# McCallum et al. (2021) https://doi.org/10.1101/2021.03.31.437925 [Preprint (BioRxiv)]
D80A,L242del;A243del;L244del;R246I;K417N;E484K;N501Y;D614G;A701V

# In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization 
# reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs. 
# [paper does not detail the P.1 variants used, using the most popular as a stand in]
# McCallum et al. (2021) https://doi.org/10.1101/2021.03.31.437925 [Preprint (BioRxiv)]
L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;H655Y;T1027I;V1176F

# VSV pseudotype B.1.351 showed 7.86-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).
# Hoffman et al. (2021) https://doi.org/10.1016/j.cell.2021.03.036 [Journal publication]
D80A;L242del;A243del;L244del;R246I;K417N;E484K;N501Y;A701V

# VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).
# Hoffman et al. (2021) https://doi.org/10.1016/j.cell.2021.03.036 [Journal publication]
L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;H655Y;T1027I;V1176F

# We analyzed 34 convalescent samples including the WHONIBSC 20/130 reference serum, and, although 
# a few sera showed near identical FRNT 50 values, the FRNT50 dilutions for the B.1.1.7 strain 
# were 2.9-fold lower (geometric mean) than those for the Victoria strain (p < 0.0001).
# Sera from 13 subjects post-B.1.1.7 infection showed no significant change in neutralization against Victoria (~wild type),
# suggesting that B.1.1.7 infection also protects against ancestral virus.
# [Note that D1119H was included in the original paper, assuming typographical error and correcting to D1118H]
# Supasa et al. (2021) https://doi.org/10.1016/j.cell.2021.02.033 [Journal publication]

# NTD-specific nAbs showed a substantial (3-450x) decrease in neutralization potency against the recently reported highly 
# transmissible B.1.1.7 variant of concern, whereas RBD-specific nAbs were either unaffected or showed lower decreases in potency.
# Graham et al. (2021) https://doi.org/10.1016/j.immuni.2021.03.023 [Journal publication]
H69del;V70del;Y144del;N501Y;A570D;D614G;P681H;T716I;S982A;D1118H

# A 1.8-fold drop in FRNT50 for B.1.351 was observed in 44 sera collected between 1 and 301 post-infection.
# Bates et al. (2021) https://doi.org/10.1101/2021.04.04.21254881 [Preprint (MedRxiv); Now published at: https://doi.org/10.1038/s41467-021-25479-6]
L18F;D80A;D215G;L242del;A243del;L244del;K417N;E484K;N501Y;D614G;A701V

# In 34 convalescent cases 4–9 weeks following infection in June 2020, before the emergence of B.1.1.7, neutralization titers 
# against B.1.351 were, on average, 13.3-fold reduced compared with an early Victoria sample (p < 0.0001). Significantly, 18 
# of 34 samples failed to reach 50% neutralization at a plasma dilution of 1:20, with a number showing a near total reduction of neutralization activity.
# In 13 convalescent cases 4–9 weeks following infection with B.1.1.7, neutralization titers 
# against B.1.351 were, on average, 3.1-fold reduced compared with an early Victoria sample (p < 0.0001). 
# Zhou et al. (2021) https://doi.org/10.1016/j.cell.2021.02.037 [Journal publication]
D80A;D215G;L242del;A243del;L244del;K417N;E484K;N501Y;D614G;A701V

# Neutralization capacity GMT of 27 subjects' sera post-infection was considerably higher (stronger) than after the second 
# Pfizer dose, and 4.5x drop in B.1.1.7 neutralization was observed.
# Collier et al. (2021) https://doi.org/10.1038/s41586-021-03412-7 [Journal publication]
H69del;V70del;Y144del;N501Y;A570D;P681H;T716I;S982A;D1118H

# Neutralization capacity GMT of 27 subjects' sera post-infection was markedly worse against B.1.1.7 + E484K than the lineage alone, with a 11.4x drop.
# Collier et al. (2021) https://doi.org/10.1038/s41586-021-03412-7 [Journal publication]
H69del;V70del;Y144del;E484K;N501Y;A570D;P681H;T716I;S982A;D1118H

# In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed 
# ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with 
# better full P.1 ID50 reciprocal value compared to the 10-mutation model.
# Wang et al. (2021) https://doi.org/10.1101/2021.03.01.433466 [Preprint (BioRxiv); Now published at: https://doi.org/10.1016/j.chom.2021.04.007]
L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;D614G;H655Y

# In a Syrian hamster model, B.1.351 variant virus had >4x reduction in YRNT90 (measure of neutralization) using wild type convalescent sera.
# PG: Note that exact sequence for B.1.351 used was not disclosed.
# Cochin et al. (2021) https://doi.org/10.1101/2021.04.19.440435 [Preprint (BioRxiv)]
D80A,L242del;A243del;L244del;R246I;K417N;E484K;N501Y;D614G;A701V

# Highly ranked escape variant in most of the early and late convalescent sera in a study of 11 post-infection subjects.
# Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003 [Journal publication]
F456A

# Highly ranked escape variant in most of the early and late convalescent sera in a study of 11 post-infection subjects.
# Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003 [Journal publication]
F456T

# In 3 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD, 
# E484P shows a resistent profile, but was mostly reduce or eliminated by  
# later time points (i.e. generally less resistant to immune cell somatic mutation evolution than E484Q of E484K), see Figure 5a,b.
# Subject C 32 days post-infection showed >>10 fold reduction in neutralization, reducing to ~10-fold by day 104.
# Subject B 26 days post-infection showed ~10 fold reduction in neutralization, but little immune escape at day 113.
# Subject G 18 days post-infection showed ~7 fold reduction in neutralization, but no immune escape at day 94.
# Notably, Subject G had no E484K/Q effect at either the early or late timepoints.
# Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003 [Journal publication]
E484P

# In 3 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD, 
# E484Q shows a notably resistant profile, comparable to or even more resistant than E484K at 
# later time points (i.e. more resistant to immune cell somatic mutation evolution), see Figure 5a,b.
# Subject C 32 days post-infection showed >>10 fold reduction in neutralization, reducing to ~10-fold by day 104.
# Subject B 26 days post-infection showed ~10 fold reduction in neutralization, reducing to ~4x at day 113.
# Notably, Subject B also showed smaller than typical (~10 vs 30+ fold) reduction in one-month neutralization by E484K at day 32, 
# and no E484K immune escape at day 104.
# Subject I 26 days post-infection showed ~10 fold reduction in neutralization, with no reduction in escape at day 102.
# Notably, Subject I also showed smaller than typical (~10 vs 30+ fold) reduction in one-month neutralization by E484K at day 26, 
# and no E484K immune escape at day 102.
# Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003 [Journal publication]
E484Q

# In 2 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD, 
# S484P shows a slightly resistent profile across both timepoints (i.e. resistant to immune cell somatic mutation evolution)
# Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003 [Journal publication]
S494P

# In 2 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD, 
# the early serum timepoint shows significant resistance (~10x or more), but both abate by the late timepoint (~3m) 
# presumably through immune cell somatic mutation evolution.
# Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003 [Journal publication]
G446V

# In 1 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD, 
# this mutation shows significant resistence (~10x) at day 26, but waning resistence at day 102 (presumably due to immune cell somatic mutation evolution).
# Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003 [Journal publication]
G485R

# Sera neutralized the B1.1.7 isolate with a lower potency (2-fold; 95% CL: 1.5 – 3-fold), and those with the lowest homotypic neutralizing potency
# had undetectable heterotypic potency (2/25).
# Skelly et al. (2021) https://doi.org/10.21203/rs.3.rs-226857/v1 [Preprint (other)]
H69del;V70del;Y144del;N501Y;A570D;D614G;P681H;L716T;A982S;D1118H

# In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably 
# above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19 
# individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels, 
# particularly against B.1.351.
# Skelly et al. (2021) https://doi.org/10.21203/rs.3.rs-226857/v1 [Preprint (other)]
L18F;D80A;D215G;L242del;A243del;K417N;E484K;N501Y;D614G;A701V

# Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera 
# collected ~8mo post Jan 2020 first wave in China).
# Hu et al. (2021) https://doi.org/10.1101/2021.01.22.427749 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41423-021-00648-1]
# Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.
# Alenquer et al. (2021) https://doi.org/10.1101/2021.04.22.441007 [Preprint (BioRxiv)]
K417N;E484K;N501Y;D614G

# Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.
# Alenquer et al. (2021) https://doi.org/10.1101/2021.04.22.441007 [Preprint (BioRxiv)]
# Subtype of the B.1.526 "New York" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in 
# IC50 serum dilution concentration for 6 convalescent sera.
# Zhou et al. (2021) https://doi.org/10.1101/2021.03.24.436620 [Preprint (BioRxiv); Now published at: https://doi.org/10.1128/mbio.01386-21]
E484K

# No notable change in neutralization efficiency, despite N439K by itself showing a ~2x decrease on average in 16 health workers' convalescent sera.
# Alenquer et al. (2021) https://doi.org/10.1101/2021.04.22.441007 [Preprint (BioRxiv)]
H69del;V70del;N439K

# Slight neutralization improvement on average in 16 health workers' convalescent sera.
# Alenquer et al. (2021) https://doi.org/10.1101/2021.04.22.441007 [Preprint (BioRxiv)]
H69del;V70del;N501Y;P681H

# Observed ~2x decrease on average in 16 health workers' convalescent sera.
# Alenquer et al. (2021) https://doi.org/10.1101/2021.04.22.441007 [Preprint (BioRxiv)]
N439K

# Observed ~2x decrease on average in 16 health workers' convalescent sera.
# Alenquer et al. (2021) https://doi.org/10.1101/2021.04.22.441007 [Preprint (BioRxiv)]
L452R

# One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.
# Alenquer et al. (2021) https://doi.org/10.1101/2021.04.22.441007 [Preprint (BioRxiv)]
H69del;V70del;N501Y;P681H

# Four the convalescent sera tested showed 4-fold or greater improvement in neutralization efficiency.
# Alenquer et al. (2021) https://doi.org/10.1101/2021.04.22.441007 [Preprint (BioRxiv)]
L5F;Q1208H

# One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.
# Alenquer et al. (2021) https://doi.org/10.1101/2021.04.22.441007 [Preprint (BioRxiv)]
H69del;V70del;N439K

# Antibody neutralization assays showed 6.7-fold resistence against 7/8 convalescent plasma.
# Deng et al. (2021) https://doi.org/10.1101/2021.03.07.21252647 [Preprint (MedRxiv); Now published at: https://doi.org/10.1016/j.cell.2021.04.025]
S13I;W152C;L452R

# The neutralizing activity of 16/20 convalescent sera was significantly lower against this pseudotyped virus model of B.1.351,
# with similar results for the live virus.
# Wang et al. (2021) https://doi.org/10.1038/s41586-021-03398-2 [Journal publication]
L18F,D80A,D215G,L242del;A243del;L244del;R246I;K417N;E484K;N501Y;D614G;A701V

# The neutralizing activity of 8/20 convalescent sera was significantly lower against this pseudotyped virus model
# Wang et al. (2021) https://doi.org/10.1038/s41586-021-03398-2 [Journal publication]
L242del;A243del;L244del

# Neutralizing antibody titers of 2/20 (10%) samples showed >10x reduction (sera collected ~1mo post Jan 2020 first wave in China).
# Neutralizing antibody titers of 8/20 samples (40%) decreased below an ID50 threshold of 40 (sera 
# collected ~8mo post Jan 2020 first wave in China).
# Hu et al. (2021) https://doi.org/10.1101/2021.01.22.427749 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41423-021-00648-1]
H69del;V70del;Y144del;N501Y;A570D;D614G;P681H;T716I;S982A;D1118H

# Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.
# Shen et al. (2021) https://doi.org/10.1101/2021.01.27.428516 [Preprint (BioRxiv); Now published at: https://doi.org/10.1016/j.chom.2021.03.002]
# In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both 
# the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.
# Rathnasinghe et al. (2021) https://doi.org/10.1101/2021.01.19.21249592 [Preprint (MedRxiv)]
N501Y

# Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.
# Shen et al. (2021) https://doi.org/10.1101/2021.01.27.428516 [Preprint (BioRxiv); Now published at: https://doi.org/10.1016/j.chom.2021.03.002]
H69del;V70del

# Neutralization activity of almost all convalescent sera tested decreased ~2x.
# Shen et al. (2021) https://doi.org/10.1101/2021.01.27.428516 [Preprint (BioRxiv); Now published at: https://doi.org/10.1016/j.chom.2021.03.002]
H69del;V70del;Y493F

# The neutralizing activity of 6/20 convalescent sera was significantly lower against this single variant pseudotyped virus model,
# showing similar patterns to the pseudotyped virus model of B.1.1.7.
# Wang et al. (2021) https://doi.org/10.1038/s41586-021-03398-2 [Journal publication]
S982A

# B.1.1.351 in 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples
# Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w [Journal publication] 
D80A,L242del;A243del;L244del;R246I;K417N;E484K;N501Y;D614G;A701V

# In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples
# Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w [Journal publication] 
K417N;E484K;N501Y 

# In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples. 
# Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w [Journal publication] 
E484K;N501Y

# B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P=0.0020.
# Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w [Journal publication] 
L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;D614G;H655Y;T1027I;V1176F

# In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P=0.0361.
# Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w [Journal publication] 
K417N

# B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P=0.0039 for mild resistence.
# Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w [Journal publication] 
L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;D614G;H655Y;T1027I;V1176F

# B.1.1.351 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P=0.0020 for moderate resistence.
# Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w [Journal publication] 
D80A,L242del;A243del;L244del;R246I;K417N;E484K;N501Y;D614G;A701V

# The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model
# Wang et al. (2021) https://doi.org/10.1038/s41586-021-03398-2 [Journal publication]
E484K

# Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest
# concentration (1:80 initial dilution) of all 4 convalescent sera tested.
# Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
E484A

# Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest
# concentration (1:80 initial dilution) of all 4 convalescent sera tested.
# Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
E484D

# Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest
# concentration (1:80 initial dilution) of all 4 convalescent sera tested.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
E484G

# Strong reduction in neutralization capability of all 4 convalescent sera tested.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
T345A

# Strong reduction in neutralization capability of all 4 convalescent sera tested.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
T345N

# Strong reduction in neutralization capability of all 4 convalescent sera tested (strongest of T345 alts).
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
T345S

# Improvement in neutralization capability of all 4 convalescent sera tested.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
R346G

# Improvement in neutralization capability of all 4 convalescent sera tested.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
A352D

# Strong reduction in neutralization capability of all 4 convalescent sera tested.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
L441R

# Ablation of neutralization capability of 3/4 convalescent sera tested.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
K444E

# Improvement in neutralization capability of all 4 convalescent sera tested.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
K444N

# Decrease in neutralization capability of all 4 convalescent sera tested (1 ablated).
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
G446D

# Ablation of neutralization capability of 3 convalescent sera tested, 1 improvement.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
G446V

# Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations).
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
N450D

# Mixed bag of positive and negative changes in neutralization capability of all 4 convalescent sera tested.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
N450K

# Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations), triple replicates.
# Against a broader panel of 16 convalescent plasma (no replicates), reductions in neutralization are considerably less dramatic 
# in pattern, and sometime neutralization increases. 
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
N450Y

# Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
L452R

# Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations).
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
S477G

# Mixed bag of mild positive and negative changes in neutralization capability of all 4 convalescent sera tested.
# Against a wider panel of 16 convalescent plasma (no replicates), 10 show low neutralization.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
S477N

# Mixed bag of positive and negative changes in neutralization capability of all 4 convalescent sera tested.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
S477R

# Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations).
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
T478I

# Mixed bag of positive and negative changes in neutralization capability of all 4 convalescent sera tested.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
F486Y

# Modest decrease in in neutralization capability of all 4 convalescent sera tested.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
F486S

# Strong reduction in neutralization capability of all 4 convalescent sera tested (3 ablations).
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
F490S

# Mixed bag of positive and negative changes in neutralization capability of all 4 convalescent sera tested.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
S494P

# General increase in neutralization capability of all 4 convalescent sera tested.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
P499L

# General increase in neutralization capability of all 4 convalescent sera tested.
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
T345A,L517R

# Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations).
# Liu et al. (2021) https://doi.org/10.1101/2020.11.06.372037 [Preprint (BioRxiv)]
S477N,S514F

# The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic
# decrease in sensitivity to neutralization of authentic 501Y.V2 variants.
# PG: I'm purposefully ignoring D614G and A701V as contributors
# Cele et al. (2021) https://doi.org/10.1038/s41586-021-03471-w [Journal publication]
L18F,D80A,D215G,L242del,A243del,L244del,K417N,E484K,N501Y

# 27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 "South African" lineage), while only 23% retained high titres 
# Wibmer et al. (2021) https://doi.org/10.1101/2021.01.18.427166 [Preprint (BioRxiv); Now published at: https://doi.org/10.1038/s41591-021-01285-x]
K417N,E484K,N501Y

# Strong positive selection (up to 72% of supernatant sequences) under six rounds of COV47 convalescent plasma passage
# Weisblum et al. (2020) https://doi.org/10.1101/2020.07.21.214759 [Preprint (BioRxiv)]
N148S

# Positive selection (up to 18% of supernatant sequences) under two rounds of COV47 convalescent plasma passage
# Weisblum et al. (2020) https://doi.org/10.1101/2020.07.21.214759 [Preprint (BioRxiv)]
K150R

# Strong positive selection (up to 40% of supernatant sequences) under three rounds of COV47 convalescent plasma passage
# Weisblum et al. (2020) https://doi.org/10.1101/2020.07.21.214759 [Preprint (BioRxiv)]
K150E

# Positive selection (up to 22% of supernatant sequences) after COV47 convalescent plasma assay
# Weisblum et al. (2020) https://doi.org/10.1101/2020.07.21.214759 [Preprint (BioRxiv)]
K150T

# Positive selection (up to 22% of supernatant sequences) under two rounds of COV47 convalescent plasma passage
# Weisblum et al. (2020) https://doi.org/10.1101/2020.07.21.214759 [Preprint (BioRxiv)]
K150Q

# Positive selection (up to 20% of supernatant sequences) under three rounds of COV47 convalescent plasma passage
# Weisblum et al. (2020) https://doi.org/10.1101/2020.07.21.214759 [Preprint (BioRxiv)]
S151P

# Positive selection (up to 20% of supernatant sequences) under two rounds of COV-NY convalescent plasma passage, eliminated in rounds three and four
# Weisblum et al. (2020) https://doi.org/10.1101/2020.07.21.214759 [Preprint (BioRxiv)]
K444R

# Positive selection (up to 14% of supernatant sequences) after COV-NY convalescent plasma assay
# Weisblum et al. (2020) https://doi.org/10.1101/2020.07.21.214759 [Preprint (BioRxiv)]
K444N

# Positive selection (up to 33% of supernatant sequences) after COV-NY convalescent plasma assay
# Weisblum et al. (2020) https://doi.org/10.1101/2020.07.21.214759 [Preprint (BioRxiv)]
K444Q

# Positive selection (up to 18% of supernatant sequences) after COV-NY convalescent plasma assay
# Weisblum et al. (2020) https://doi.org/10.1101/2020.07.21.214759 [Preprint (BioRxiv)]
V445E

# Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma
# Kemp et al. (2020) https://doi.org/10.1101/2020.12.05.20241927 [Preprint (MedRxiv); Now published at: https://doi.org/10.1038/s41586-021-03291-y]
D796H, H69del, V70del

# 36% of virions contained this variant (in the S-protein NTD N3 loop) after 7 passages (45 days) in convalescent plasma PT188
# This variant became 100% in subsequent passage with decreased neutralizing titer.
# It is hypothesized that the F140 deletion alters the packing of the N1, N3 and N5 loops
# Andreano et al. (2020) https://doi.org/10.1101/2020.12.28.424451 [Preprint (BioRxiv); Now published at: https://doi.org/10.1073/pnas.2103154118]
F140del

# This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity
# Andreano et al. (2020) https://doi.org/10.1101/2020.12.28.424451 [Preprint (BioRxiv); Now published at: https://doi.org/10.1073/pnas.2103154118]
E484K

# Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)
# Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012 [Journal publication]
Y145del

# Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)
# Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012 [Journal publication]
Q414E

# Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)
# Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012 [Journal publication]
N439K

# Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)
# Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012 [Journal publication]
G446V

# Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)
# Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012 [Journal publication]
K458N

# Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)
# Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012 [Journal publication]
I472V

# Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)
# Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012 [Journal publication]
A475V

# Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)
# Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012 [Journal publication]
T478I

# Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)
# Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012 [Journal publication]
V483I

# Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)
# Resistent to 3 individual sera at >4x
# Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012 [Journal publication]
F490L

# Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)
# Resistent to 3 individual sera at >4x
# Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012 [Journal publication]
H519P

# Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)
# Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012 [Journal publication]
A831V
